KR102906523B1 - 수용체-상호작용 단백질 키나제 1 (ripk1) 억제제로서의 1h-인다졸 카르복스아미드 - Google Patents
수용체-상호작용 단백질 키나제 1 (ripk1) 억제제로서의 1h-인다졸 카르복스아미드Info
- Publication number
- KR102906523B1 KR102906523B1 KR1020217010498A KR20217010498A KR102906523B1 KR 102906523 B1 KR102906523 B1 KR 102906523B1 KR 1020217010498 A KR1020217010498 A KR 1020217010498A KR 20217010498 A KR20217010498 A KR 20217010498A KR 102906523 B1 KR102906523 B1 KR 102906523B1
- Authority
- KR
- South Korea
- Prior art keywords
- methyl
- carbamoyl
- indazole
- carboxamide
- phenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862730602P | 2018-09-13 | 2018-09-13 | |
| US62/730,602 | 2018-09-13 | ||
| PCT/US2019/050719 WO2020056072A1 (en) | 2018-09-13 | 2019-09-12 | 1h-indazole carboxamides as receptor-interacting protein kinase 1 inhibitors (ripk1) |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20210060517A KR20210060517A (ko) | 2021-05-26 |
| KR102906523B1 true KR102906523B1 (ko) | 2025-12-30 |
Family
ID=68073171
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020217010498A Active KR102906523B1 (ko) | 2018-09-13 | 2019-09-12 | 수용체-상호작용 단백질 키나제 1 (ripk1) 억제제로서의 1h-인다졸 카르복스아미드 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US12172975B2 (https=) |
| EP (1) | EP3849968B1 (https=) |
| JP (1) | JP7599411B2 (https=) |
| KR (1) | KR102906523B1 (https=) |
| CN (1) | CN112673000B (https=) |
| AU (1) | AU2019337612A1 (https=) |
| BR (1) | BR112021004385A2 (https=) |
| CA (1) | CA3112735A1 (https=) |
| EA (1) | EA202190718A1 (https=) |
| ES (1) | ES2936481T3 (https=) |
| IL (1) | IL281370A (https=) |
| MX (1) | MX2021002509A (https=) |
| SG (1) | SG11202102405YA (https=) |
| WO (1) | WO2020056072A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE058292T2 (hu) | 2017-10-30 | 2022-07-28 | Bristol Myers Squibb Co | Aminoimidazopiridazinok mint kináz inhibitorok |
| CN112262139B (zh) | 2018-01-26 | 2023-07-25 | 百时美施贵宝公司 | 作为激酶抑制剂的氨基吡咯并三嗪 |
| AU2019339355A1 (en) | 2018-09-13 | 2021-05-13 | Bristol-Myers Squibb Company | Indazole carboxamides as kinase inhibitors |
| ES2969756T3 (es) * | 2019-10-03 | 2024-05-22 | Bristol Myers Squibb Co | Indazol carboxamidas como inhibidores de cinasas |
| EP4214207A4 (en) | 2020-09-15 | 2024-10-02 | 1st Biotherapeutics, Inc. | 2-AMINO-3-CARBONYL IMIDAZOPYRIDINE AND PYRAZOLOPYRIDINE COMPOUNDS |
| AR123793A1 (es) | 2020-10-19 | 2023-01-11 | Bristol Myers Squibb Co | Compuestos de triazolopiridinilo como inhibidores de quinasas |
| WO2025106362A1 (en) * | 2023-11-16 | 2025-05-22 | Merck Sharp & Dohme Llc | Ripk1 inhibitors and methods of use |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013100672A1 (ko) | 2011-12-29 | 2013-07-04 | 제이더블유중외제약㈜ | 단백질 키나아제 저해활성을 가지는 3,6-이치환된 인다졸 유도체 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4836788B2 (ja) | 2003-07-23 | 2011-12-14 | エグゼリクシス， インコーポレイテッド | 未分化リンパ腫キナーゼ変調因子及びその使用法 |
| RU2418797C2 (ru) | 2004-12-22 | 2011-05-20 | Мемори Фармасьютиклз Корпорейшн | Лиганды никотинового рецептора альфа-7, их получение и применение |
| UA92083C2 (ru) | 2006-05-19 | 2010-09-27 | Эбботт Леборетриз | Азабициклические алкановые производные, замещенные конденсированным бициклогетероциклом |
| KR101061599B1 (ko) | 2008-12-05 | 2011-09-02 | 한국과학기술연구원 | 비정상 세포 성장 질환의 치료를 위한 단백질 키나아제 저해제인 신규 인다졸 유도체, 이의 약학적으로 허용가능한염 및 이를 유효성분으로 함유하는 약학적 조성물 |
| WO2010068287A2 (en) | 2008-12-11 | 2010-06-17 | Angion Biomedica Corp. | Small molecule modulators of hepatocyte growth factor (scatter factor) activity |
| EA020017B1 (ru) | 2009-04-30 | 2014-08-29 | Новартис Аг | Производные имидазола и их применение в качестве модуляторов циклинзависимых киназ |
| US8455516B2 (en) | 2010-01-15 | 2013-06-04 | Touro University | HIV-1 fusion inhibitors and methods |
| RS54539B1 (sr) | 2012-02-21 | 2016-06-30 | Aziende Chimiche Riunite Angelini Francesco - A.C.R.A.F. - S.P.A. | Upotreba 1h-indazol-3-karboksamidnih jedinjenja kao inhibitora kinaze 3-beta glikogen sintetaze |
| CA2860250C (en) | 2012-02-21 | 2020-11-10 | Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A. | 1h-indazole-3-carboxamide compounds as glycogen synthase kinase 3 beta inhibitors |
| WO2014047024A1 (en) | 2012-09-18 | 2014-03-27 | Bristol-Myers Squibb Company | Iap antagonists |
| CN104781251B (zh) * | 2012-11-08 | 2016-12-14 | 百时美施贵宝公司 | 可作为激酶调节剂的经双环杂环取代的吡啶基化合物 |
| MX2016012208A (es) | 2014-03-20 | 2017-01-26 | Samumed Llc | Indazol-3-carboxamidas 5-substituidas y preparacion y uso de las mismas. |
| EP3463355B1 (en) | 2016-05-26 | 2024-08-28 | Sonic Master Limited | Modulators of dux4 for regulation of muscle function |
| MA47460A (fr) | 2017-02-13 | 2019-12-18 | Bristol Myers Squibb Co | Aminotriazolopyridines utilisées en tant qu'inhibiteurs de kinase |
| HUE058292T2 (hu) | 2017-10-30 | 2022-07-28 | Bristol Myers Squibb Co | Aminoimidazopiridazinok mint kináz inhibitorok |
| CN112262139B (zh) | 2018-01-26 | 2023-07-25 | 百时美施贵宝公司 | 作为激酶抑制剂的氨基吡咯并三嗪 |
| AU2019339355A1 (en) | 2018-09-13 | 2021-05-13 | Bristol-Myers Squibb Company | Indazole carboxamides as kinase inhibitors |
| ES2969756T3 (es) | 2019-10-03 | 2024-05-22 | Bristol Myers Squibb Co | Indazol carboxamidas como inhibidores de cinasas |
-
2019
- 2019-09-12 KR KR1020217010498A patent/KR102906523B1/ko active Active
- 2019-09-12 BR BR112021004385-3A patent/BR112021004385A2/pt not_active Application Discontinuation
- 2019-09-12 US US17/274,220 patent/US12172975B2/en active Active
- 2019-09-12 SG SG11202102405YA patent/SG11202102405YA/en unknown
- 2019-09-12 MX MX2021002509A patent/MX2021002509A/es unknown
- 2019-09-12 EA EA202190718A patent/EA202190718A1/ru unknown
- 2019-09-12 ES ES19779240T patent/ES2936481T3/es active Active
- 2019-09-12 WO PCT/US2019/050719 patent/WO2020056072A1/en not_active Ceased
- 2019-09-12 JP JP2021513958A patent/JP7599411B2/ja active Active
- 2019-09-12 AU AU2019337612A patent/AU2019337612A1/en not_active Abandoned
- 2019-09-12 EP EP19779240.1A patent/EP3849968B1/en active Active
- 2019-09-12 CA CA3112735A patent/CA3112735A1/en active Pending
- 2019-09-12 CN CN201980059445.8A patent/CN112673000B/zh active Active
-
2021
- 2021-03-09 IL IL281370A patent/IL281370A/en unknown
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013100672A1 (ko) | 2011-12-29 | 2013-07-04 | 제이더블유중외제약㈜ | 단백질 키나아제 저해활성을 가지는 3,6-이치환된 인다졸 유도체 |
Non-Patent Citations (1)
| Title |
|---|
| Clinica Chimica Acta. 2011, Vol. 412, Issues 7-8, pp. 513-520 |
Also Published As
| Publication number | Publication date |
|---|---|
| CA3112735A1 (en) | 2020-03-19 |
| KR20210060517A (ko) | 2021-05-26 |
| CN112673000A (zh) | 2021-04-16 |
| US20220380335A1 (en) | 2022-12-01 |
| EP3849968A1 (en) | 2021-07-21 |
| SG11202102405YA (en) | 2021-04-29 |
| EP3849968B1 (en) | 2022-12-21 |
| ES2936481T3 (es) | 2023-03-17 |
| AU2019337612A1 (en) | 2021-05-13 |
| CN112673000B (zh) | 2024-10-18 |
| BR112021004385A2 (pt) | 2021-07-20 |
| JP7599411B2 (ja) | 2024-12-13 |
| US12172975B2 (en) | 2024-12-24 |
| JP2022500418A (ja) | 2022-01-04 |
| IL281370A (en) | 2021-04-29 |
| WO2020056072A1 (en) | 2020-03-19 |
| EA202190718A1 (ru) | 2021-07-01 |
| MX2021002509A (es) | 2021-04-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102906523B1 (ko) | 수용체-상호작용 단백질 키나제 1 (ripk1) 억제제로서의 1h-인다졸 카르복스아미드 | |
| KR102549952B1 (ko) | 키나제 억제제로서의 아미노트리아졸로피리딘 | |
| JP5487214B2 (ja) | キナーゼ阻害剤として有用なカルバゾールカルボキシアミド化合物 | |
| US11440913B2 (en) | Aminoimidazopyridazines as kinase inhibitors | |
| KR102793119B1 (ko) | 키나제 억제제로서의 인다졸 카르복스아미드 | |
| US12275721B2 (en) | Indazole carboxamides as kinase inhibitors | |
| EA042124B1 (ru) | Аминоимидазопиридазины в качестве ингибиторов киназ |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| R18-X000 | Changes to party contact information recorded |
St.27 status event code: A-3-3-R10-R18-oth-X000 |
|
| A201 | Request for examination | ||
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PA0201 | Request for examination |
St.27 status event code: A-1-2-D10-D11-exm-PA0201 |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
St.27 status event code: A-1-2-D10-D21-exm-PE0902 |
|
| T11-X000 | Administrative time limit extension requested |
St.27 status event code: U-3-3-T10-T11-oth-X000 |
|
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| E90F | Notification of reason for final refusal | ||
| PE0902 | Notice of grounds for rejection |
St.27 status event code: A-1-2-D10-D21-exm-PE0902 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| D22 | Grant of ip right intended |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D22-EXM-PE0701 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| PE0701 | Decision of registration |
St.27 status event code: A-1-2-D10-D22-exm-PE0701 |
|
| F11 | Ip right granted following substantive examination |
Free format text: ST27 STATUS EVENT CODE: A-2-4-F10-F11-EXM-PR0701 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| PR0701 | Registration of establishment |
St.27 status event code: A-2-4-F10-F11-exm-PR0701 |
|
| PR1002 | Payment of registration fee |
St.27 status event code: A-2-2-U10-U12-oth-PR1002 Fee payment year number: 1 |
|
| U12 | Designation fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U12-OTH-PR1002 (AS PROVIDED BY THE NATIONAL OFFICE) Year of fee payment: 1 |
|
| PG1601 | Publication of registration |
St.27 status event code: A-4-4-Q10-Q13-nap-PG1601 |
|
| Q13 | Ip right document published |
Free format text: ST27 STATUS EVENT CODE: A-4-4-Q10-Q13-NAP-PG1601 (AS PROVIDED BY THE NATIONAL OFFICE) |